Loading…
Loading…
DYN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DYN and 80,000+ other tickers.
See exactly how DYN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DYN and 80,000+ other tickers.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 25.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,800,099 shares of the company's stock after selling 2,330,366 shares during the
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present preclinical data supporting the ongoing development of DYNE-253, DYNE-245, DYNE-244 and DYNE-255 for the potential treatment of DMD amenable to skipping of exons 53, 45, 44 and 55, respectively, at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting being held September 25-27, 2026, in San Antonio, TX.
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
ADAR1 Capital Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 42,821 shares of the company's stock, valued at approximately $951,000. Other institutional investors
Deutsche Bank AG purchased a new position in Dyne Therapeutics, Inc. (NASDAQ: DYN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 242,392 shares of the company's stock, valued at approximately $5,384,000. Deutsche Bank AG owned approximately